These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18507746)

  • 1. The use and abuse of surrogate endpoints in clinical research in transfusion medicine.
    Arnold DM; Lim W
    Transfusion; 2008 Aug; 48(8):1547-9. PubMed ID: 18507746
    [No Abstract]   [Full Text] [Related]  

  • 2. Surrogate and mediating endpoints: current status and future directions.
    Prentice RL
    J Natl Cancer Inst; 2009 Feb; 101(4):216-7. PubMed ID: 19211455
    [No Abstract]   [Full Text] [Related]  

  • 3. Surrogate measures of outcome in clinical trials: clues worth examining?
    Carter BS; Awad IA
    Neurosurgery; 2008 Aug; 63(2):N5. PubMed ID: 18797341
    [No Abstract]   [Full Text] [Related]  

  • 4. An inexplicable oversight and a misconception in research.
    Ingenbleek Y; Cynober L
    J Nutr Health Aging; 2005; 9(3):199. PubMed ID: 15864401
    [No Abstract]   [Full Text] [Related]  

  • 5. Surrogate end points cloud DES trials.
    Kahn J
    J Interv Cardiol; 2006 Feb; 19(1):117-9. PubMed ID: 16483352
    [No Abstract]   [Full Text] [Related]  

  • 6. The top ten list of randomized controlled trials in transfusion medicine.
    Blajchman MA
    Vox Sang; 2004 Jul; 87 Suppl 2():193-6. PubMed ID: 15209915
    [No Abstract]   [Full Text] [Related]  

  • 7. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
    Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
    Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug markers questioned.
    Ledford H
    Nature; 2008 Apr; 452(7187):510-1. PubMed ID: 18385695
    [No Abstract]   [Full Text] [Related]  

  • 9. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Primary prevention of dementia in Alzheimer's disease: a perspective from prevention research in cardiovascular disease and stroke.
    Fillit H; Nash DT; Shineman D
    Alzheimers Dement; 2009 Mar; 5(2):149-53. PubMed ID: 19328448
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of treatment benefits: clinical endpoints relevant to patients.
    Prescrire Int; 2008 Dec; 17(98):260. PubMed ID: 19425279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismanaged measures.
    Nature; 2008 Apr; 452(7187):504. PubMed ID: 18385690
    [No Abstract]   [Full Text] [Related]  

  • 13. Surrogate endpoints: wishful thinking or reality?
    Burzykowski T
    Stat Methods Med Res; 2008 Oct; 17(5):463-6. PubMed ID: 18413334
    [No Abstract]   [Full Text] [Related]  

  • 14. Endpoints in clinical trials on transfusion requirements: the need for a structured approach.
    Hardy JF
    Transfusion; 2005 Jul; 45(1 Suppl):9S-13S. PubMed ID: 15989686
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial: clinical trials in tropical diseases: a politically incorrect view.
    White NJ
    Trop Med Int Health; 2006 Oct; 11(10):1483-4. PubMed ID: 17002721
    [No Abstract]   [Full Text] [Related]  

  • 16. You get what you measure: evaluating endpoints in MS clinical trials.
    Marrie RA
    Neurology; 2008 Aug; 71(9):620-1. PubMed ID: 18685132
    [No Abstract]   [Full Text] [Related]  

  • 17. Surrogate markers in clinical studies: problems solved or created?
    Manns B; Owen WF; Winkelmayer WC; Devereaux PJ; Tonelli M
    Am J Kidney Dis; 2006 Jul; 48(1):159-66. PubMed ID: 16797400
    [No Abstract]   [Full Text] [Related]  

  • 18. Pilot trials in clinical research: of what value are they?
    Loscalzo J
    Circulation; 2009 Apr; 119(13):1694-6. PubMed ID: 19349331
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
    Di Maio M; Daniele B; Gallo C; Perrone F
    J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
    [No Abstract]   [Full Text] [Related]  

  • 20. Reassessing the validity of surrogate markers of drug efficacy in the treatment of coronary artery disease.
    Colatsky TJ
    Curr Opin Investig Drugs; 2009 Mar; 10(3):239-44. PubMed ID: 19333881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.